Celgene (CELG) is the only large-cap biotech that provides investors with long-range financial guidance. It’s a risky strategy that pays off well when the business is humming but can backfire quickly if plans run off the rails.

The latter just happened to Celgene. A weaker outlook for several of its drugs plus one big pipeline blowup forced Celgene to make a deep cut in its 2020 revenue guidance on Thursday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy